BACKGROUND: It is not known whether geographic differences in the prevalence of chronic kidney disease exist and are associated with end-stage renal disease (ESRD) incidence rates across the United States. STUDY DESIGN: Cross-sectional and ecologic. SETTING & PARTICIPANTS: White (n = 16,410) and black (n = 11,109) participants from across the continental United States in the population-based Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. PREDICTOR: Geographic region, defined by the 18 networks of the US ESRD Network Program. OUTCOMES & MEASUREMENTS: Albuminuria, defined as albumin-creatinine ratio ≥30 mg/g, and decreased estimated glomerular filtration rate (eGFR), defined as <60 mL/min/1.73 m(2), were measured in the REGARDS Study. ESRD incidence rates were obtained from the US Renal Data System. RESULTS: For whites, the network-specific prevalence of albuminuria ranged from 8.4% (95% CI, 3.3%-13.5%) in Network 15 to 14.8% (95% CI, 8.0%-21.6%) in Network 3, and decreased eGFR ranged from 4.3% (95% CI, 2.0%-6.6%) in Network 4 to 16.7% (95% CI, 12.7%-20.7%) in Network 7. For blacks, the prevalence of albuminuria ranged from 12.1% (95% CI, 8.7%-15.5%) in Network 5 to 26.5% (95% CI, 16.7%-36.3%) in Network 4, and decreased eGFR ranged from 6.7% (95% CI, 5.0%-8.4%) in Network 17/18 to 13.4% (95% CI, 7.8%-19.1%) in Network 12. Spearman correlation coefficients for the prevalence of albuminuria and decreased eGFR with network-specific ESRD incidence rates were 0.49 and 0.24, respectively, for whites and 0.29 and 0.25, respectively, for blacks. LIMITATIONS: There were few cases of albuminuria and decreased eGFR in some geographic regions. CONCLUSIONS: In the United States, substantial geographic variations in the prevalence of albuminuria and decreased eGFR exist, but were correlated only modestly with ESRD incidence, suggesting the chronic kidney disease burden may not explain the geographic variation in ESRD incidence.
BACKGROUND: It is not known whether geographic differences in the prevalence of chronic kidney disease exist and are associated with end-stage renal disease (ESRD) incidence rates across the United States. STUDY DESIGN: Cross-sectional and ecologic. SETTING & PARTICIPANTS: White (n = 16,410) and black (n = 11,109) participants from across the continental United States in the population-based Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. PREDICTOR: Geographic region, defined by the 18 networks of the US ESRD Network Program. OUTCOMES & MEASUREMENTS: Albuminuria, defined as albumin-creatinine ratio ≥30 mg/g, and decreased estimated glomerular filtration rate (eGFR), defined as <60 mL/min/1.73 m(2), were measured in the REGARDS Study. ESRD incidence rates were obtained from the US Renal Data System. RESULTS: For whites, the network-specific prevalence of albuminuria ranged from 8.4% (95% CI, 3.3%-13.5%) in Network 15 to 14.8% (95% CI, 8.0%-21.6%) in Network 3, and decreased eGFR ranged from 4.3% (95% CI, 2.0%-6.6%) in Network 4 to 16.7% (95% CI, 12.7%-20.7%) in Network 7. For blacks, the prevalence of albuminuria ranged from 12.1% (95% CI, 8.7%-15.5%) in Network 5 to 26.5% (95% CI, 16.7%-36.3%) in Network 4, and decreased eGFR ranged from 6.7% (95% CI, 5.0%-8.4%) in Network 17/18 to 13.4% (95% CI, 7.8%-19.1%) in Network 12. Spearman correlation coefficients for the prevalence of albuminuria and decreased eGFR with network-specific ESRD incidence rates were 0.49 and 0.24, respectively, for whites and 0.29 and 0.25, respectively, for blacks. LIMITATIONS: There were few cases of albuminuria and decreased eGFR in some geographic regions. CONCLUSIONS: In the United States, substantial geographic variations in the prevalence of albuminuria and decreased eGFR exist, but were correlated only modestly with ESRD incidence, suggesting the chronic kidney disease burden may not explain the geographic variation in ESRD incidence.
Authors: David H Smith; Christina M Gullion; Gregory Nichols; Douglas Scott Keith; Jonathan Betz Brown Journal: J Am Soc Nephrol Date: 2004-05 Impact factor: 10.121
Authors: Allan J Collins; Shuling Li; David T Gilbertson; Jiannong Liu; Shu-Cheng Chen; Charles A Herzog Journal: Kidney Int Suppl Date: 2003-11 Impact factor: 10.545
Authors: Lorien S Dalrymple; Ronit Katz; Bryan Kestenbaum; Michael G Shlipak; Mark J Sarnak; Catherine Stehman-Breen; Stephen Seliger; David Siscovick; Anne B Newman; Linda Fried Journal: J Gen Intern Med Date: 2010-09-19 Impact factor: 5.128
Authors: Katharina Brück; Vianda S Stel; Giovanni Gambaro; Stein Hallan; Henry Völzke; Johan Ärnlöv; Mika Kastarinen; Idris Guessous; José Vinhas; Bénédicte Stengel; Hermann Brenner; Jerzy Chudek; Solfrid Romundstad; Charles Tomson; Alfonso Otero Gonzalez; Aminu K Bello; Jean Ferrieres; Luigi Palmieri; Gemma Browne; Vincenzo Capuano; Wim Van Biesen; Carmine Zoccali; Ron Gansevoort; Gerjan Navis; Dietrich Rothenbacher; Pietro Manuel Ferraro; Dorothea Nitsch; Christoph Wanner; Kitty J Jager Journal: J Am Soc Nephrol Date: 2015-12-23 Impact factor: 10.121
Authors: Gabriela R Oates; Bradford E Jackson; Edward E Partridge; Karan P Singh; Mona N Fouad; Sejong Bae Journal: Am J Prev Med Date: 2017-01 Impact factor: 5.043
Authors: Casey M Rebholz; Josef Coresh; Shoshana H Ballew; Blaithin McMahon; Seamus P Whelton; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2015-03-12 Impact factor: 8.860
Authors: Jonathan J Suarez; Tamara Isakova; Cheryl A M Anderson; L Ebony Boulware; Myles Wolf; Julia J Scialla Journal: Am J Prev Med Date: 2015-12 Impact factor: 5.043
Authors: Bradford E Jackson; Gabriela R Oates; Karan P Singh; James M Shikany; Mona N Fouad; Edward E Partridge; Sejong Bae Journal: Ethn Health Date: 2016-09-29 Impact factor: 2.772